LONG BEACH, Calif. — In this video from the American Society of Retina Specialists annual meeting, Roger A. Goldberg, MD, MBA, discusses the GALE study and the outcomes of early vs. later pegcetacoplan in patients with geographic atrophy.
“In the best performing group, which was the nonsubfoveal population, we see that 4 years of continuous therapy, monthly treatment with Syfovre (pegcetacoplan, Apellis Pharmaceuticals), leads to 3.16 mm2 of tissue saved. That’s about 1.5 disc areas or two foveal areas, so quite a significant amount of tissue,” Goldberg, of Bay Area